Premium
Aclarubicin in the treatment of relapsed or resistant acute myelogenous leukaemia: a phase II trial
Author(s) -
Evensen S. A.,
Wisøff F.,
Müller E.,
Talstad I.,
Waage A.,
Johansen L.
Publication year - 1987
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1987.tb00021.x
Subject(s) - aclarubicin , medicine , daunorubicin , chemotherapy , refractory (planetary science) , complete remission , gastroenterology , oncology , physics , astrobiology
SUMMARY Nineteen patients with acute myelogenous leukaemia refractory to regimens including daunorubicin (relapsed or resistant to the induction treatment) received aclarubicin as single‐agent chemotherapy in a dose of 40 mg/m 2 daily for 5–7 days. Among 17 evaluable patients one achieved complete remission, and two obtained partial remission. Side effects were acceptable. The chosen dose of aclarubicin appeared to be suboptimal. However, several arguments suggest that aclarubicin in combination with other cytotoxic agents should be evaluated as first‐line chemotherapy of acute myelogenous leukaemia.